Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of intrathecal tominersen (RO7234292/RG6042) in Huntington's disease
2018-003898-94Phase 3Unknown
- Sponsor
- Roche
- Start
- Dec 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tominersen in Huntington disease (HD), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Status: unknown.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2018-003898-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003898-94.